MelanA polyclonal Antibody | BS90846

MelanA polyclonal Antibody | BS90846 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Application: WB IHC FC

Application Range: WB:1:1,000-1:2,000 FC:1:50-1:100 IHC:1:50-1:200

Background: Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients.

Storage & Stability: Store at +4°C after thawing. Aliquot store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Specificity: MelanA polyclonal Antibody detects endogenous levels of MelanA protein.

Molecular Weight: 20 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: MLANA, Antigen LB39 AA, Antigen LB39-AA, Antigen SK29 AA, Antigen SK29-AA, MAR1, MART 1, MART-1, MART1, Melan A, Melan A protein, Melanoma antigen recognized by T cells 1, Melanoma antigen recognized by T-cells 1, MLAN A, MLANA, OTTHUMP00000021036, OTTHUMP00000021037, OTTHUMP00000021038, Protein Melan-A,

Immunogen: recombinant protein

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: ProA affinity purified

Pathway: